Analyze Diet

Cardiorespiratory and metabolic effects of xylazine, detomidine, and a combination of xylazine and acepromazine administered after exercise in horses.

Abstract: To determine sedative, cardiorespiratory and metabolic effects of xylazine hydrochloride, detomidine hydrochloride, and a combination of xylazine and acepromazine administered i.v. at twice the standard doses in Thoroughbred horses recuperating from a brief period of maximal exercise. Methods: 6 adult Thoroughbreds. Methods: Horses were preconditioned by exercising them on a treadmill to establish a uniform level of fitness. Each horse ran 4 simulated races, with a minimum of 14 days between races. Simulated races were run at a treadmill speed that caused horses to exercise at 120% of their maximal oxygen consumption. Horses ran until they were fatigued or for a maximum of 2 minutes. One minute after the end of exercise, horses were treated i.v. with xylazine (2.2 mg/kg of body weight), detomidine (0.04 mg/kg), a combination of xylazine (2.2 mg/kg) and acepromazine (0.04 mg/kg), or saline (0.9% NaCl) solution. Treatments were randomized so that each horse received each treatment once, in random order. Cardiopulmonary indices were measured, and samples of arterial and venous blood were collected immediately before and at specific times for 90 minutes after the end of each race. Results: All sedatives produced effective sedation. The cardiopulmonary depression that was induced was qualitatively similar to that induced by administration of these sedatives to resting horses and was not severe. Sedative administration after exercise prolonged the exercise-induced increase in body temperature. Conclusions: Administration of xylazine, detomidine, or a combination of xylazine-acepromazine at twice the standard doses produced safe and effective sedation in horses that had just undergone a brief, intense bout of exercise.
Publication Date: 2000-05-03 PubMed ID: 10791941
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research sought to understand the sedative, cardiorespiratory, and metabolic effects of xylazine hydrochloride, detomidine hydrochloride, and a combination of xylazine and acepromazine when administered at double the standard dose to Thoroughbred horses post-exercise.

Research Methodology

  • The research involved 6 adult Thoroughbred horses which were preconditioned on a treadmill to establish a uniform fitness level.
  • Each horse was made to run 4 simulated races with at least 14 days intervening between each race. The treadmill speed was set to a level that made the horses exercise at 120% of their maximum oxygen consumption.
  • The horses ran until they were fatigued or for a maximum of 2 minutes.
  • One minute after the end of exercise, the horses were given intravenous (i.v.) treatments with xylazine (2.2 mg/kg of body weight), detomidine (0.04 mg/kg), a combination of xylazine (2.2 mg/kg) and acepromazine (0.04 mg/kg), or a saline (0.9% Sodium Chloride) solution.
  • These treatments were randomized so that each horse received all treatments once, in a random order.
  • Cardiopulmonary indices were measured and samples of arterial and venous blood were collected right before and at specific times for 90 minutes after each race.

Research Findings

  • All the sedatives were found to produce effective sedation in the horses.
  • Cardiopulmonary depression, a condition where the heart and lungs do not function optimally, was induced by the administration of these sedatives. This depression was qualitatively the same as that induced by administering these sedatives to resting horses, and was not severe.
  • The administration of sedatives after exercise was found to prolong the exercise-induced increase in body temperature.

Research Conclusion

  • It was concluded that administering xylazine, detomidine, or a combination of xylazine-acepromazine at twice the standard doses produces safe and effective sedation in horses that have just undergone intense, short bouts of exercise.

Cite This Article

APA
Hubbell JA, Hinchcliff KW, Schmall LM, Muir WW, Robertson JT, Sams RA. (2000). Cardiorespiratory and metabolic effects of xylazine, detomidine, and a combination of xylazine and acepromazine administered after exercise in horses. Am J Vet Res, 60(10), 1271-1279.

Publication

ISSN: 0002-9645
NlmUniqueID: 0375011
Country: United States
Language: English
Volume: 60
Issue: 10
Pages: 1271-1279

Researcher Affiliations

Hubbell, J A
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus 43210, USA.
Hinchcliff, K W
    Schmall, L M
      Muir, W W
        Robertson, J T
          Sams, R A

            MeSH Terms

            • Acepromazine / pharmacology
            • Analgesics / pharmacology
            • Animals
            • Blood Pressure / drug effects
            • Carbon Dioxide / blood
            • Cardiac Output / drug effects
            • Drug Interactions
            • Female
            • Heart Rate / drug effects
            • Hemodynamics / drug effects
            • Horses
            • Hypnotics and Sedatives / pharmacology
            • Imidazoles / pharmacology
            • Male
            • Oxygen / blood
            • Oxygen Consumption / drug effects
            • Physical Conditioning, Animal
            • Physical Exertion / physiology
            • Pulmonary Artery / physiology
            • Vascular Resistance / drug effects
            • Xylazine / pharmacology

            Citations

            This article has been cited 1 times.
            1. Thakur BP, Sharma SK, Sharma A, Kumar A. Clinical Evaluation of Xylazine-Butorphanol-Guaifenesin-Ketamine as Short-Term TIVA in Equines. Vet Med Int 2011;2011:506831.
              doi: 10.4061/2011/506831pubmed: 21647339google scholar: lookup